Original Source(s)
Related Content
GLP-1 Drugs Tied to Lower Addiction Risk
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
May 27, 2026
-
5 min
RA Prescribing Patterns Shift Over 15 Years
An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.
May 29, 2026
-
5 min
FDA Expands Afrezza to Pediatric Diabetes
The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.
May 29, 2026
-
3 min
